Intazol 400 mg (1 tablet)

The instruction for medical use of Intazol Torgovoye medicine a name Intazol Mezhdunarodnoye the unlicensed name Albendazol Lekarstvennaya a form of the Tablet, 400 mg Structure One tablet contains active agent - an albendazol of 400 mg, excipients: Mannitolum, lactoses monohydrate, aspartame, dye a yellow sunset of FCF (E110), sodium lauryl sulfate, starch corn, the water purified of sodium of starch glikolit, cellulose microcrystalline, essence orange, powder, magnesium stearate, silicon dioxide colloidal. The description of the Tablet of a capsulovidny form, orange color, with the line of a break on one party. Pharmacotherapeutic group Drugs for treatment of a nematodosis. Benzimidazole derivatives. Albendazol. The ATX P02CA03 code the Pharmacological Pharmacokinetics Later properties of oral administration albendazol is badly absorbed from a gastro intestinal path (less than 5%), in not changed look the bioavailability - low is not defined in plasma. Systemic pharmacological action increases if the drug is taken with greasy food which increases absorption and the maximum concentration in plasma (Cmax) by 5 times. The % plasmas-70 connected with proteins. Is defined in urine, bile, a liver, a wall of a cyst, cystous liquid and cerebrospinal fluid. Albendazol quickly turns in a liver into primary metabolite, an albendazol sulphoxide which is metabolized further to an albendazol of sulphone and other oxidized metabolites. Elimination half-life of an albendazol of sulphoxide makes of blood plasma 8-12chas. Albendazol sulphoxide and other metabolites are removed mainly with bile, and only a small amount is removed with urine. A pharmacodynamics Albendazol - derivative carbamate benzimidazole, antiprotozoan and anthelminthic drug of a broad spectrum of activity. Albendazol breaks processes of transport of glucose, suppresses polymerization beta tubulina, causes dysfunction of the microtubular device in a helminth organism that leads to his death and removal from a human body. Indications - neurotsistitsirkoz - cystous echinococcosis the Route of administration and doses take the Drug inside together with meal. Reception at the same time is preferable day. Some patients can have difficulties with ingestion of a tablet, in such cases the tablet can be chewed and washed down with a small amount of water or to pound. If there does not occur recovery in three weeks, the second year of treatment registers. The mode of dosing is set individually depending on age, body weight and also from severity of an infection. The dose for patients at body weight more than 60 kg makes 400 mg 2 times a day. Weighing less than 60 kg drug is appointed at the rate of 15 mg/kg / in day. This dose has to be divided into 2 receptions. The maximum daily dose makes 800 mg. Neurocysticercosis: Duration of reception from 7 to 30 days, in dependence of the response of the patient to the carried-out therapy. The second year can be repeated after a two-week break in administration of drug. Cystous echinococcosis: Intazol is appointed in case of inoperable pathology, before surgery, in the post-operational period when the course of preoperative therapy was too short or viable cysts, after chrezkozhny drainage of cysts are found in the diagnostic or therapeutic purposes. The course of treatment makes 28 days. At an inoperable form of peritoneal cysts, cysts in lungs and a liver three 28-day cycles of treatment divided by a 14-day break in administration of drug are recommended. In the presence of cysts in a brain and bones longer course of therapy can be required. Before operation two 28-day cycles divided by a 14-day break in administration of drug are recommended. If surgical intervention is necessary until the termination of a two-cyclic course, Intazol is appointed in case of inoperable has to be accepted until surgery. If the presurgical course was less than 14 days or viable cysts are found, then after operation carry out two cycles for 28 days divided by a 14-day break in administration of drug. Side effects Short-term therapy by low doses Sometimes - a headache and dizziness - pain in the field of epigastrium or a stomach, nausea, vomiting and diarrhea Seldom - reactions of hypersensitivity, including rash, an itching and urticaria - increase in level of liver enzymes is Very rare - a multiformny erythema, Stephens-Johnson's syndrome Long-term therapy by high doses Very often - a headache - slight or average increase of level of hepatic enzymes Is frequent - dizziness - an abdominal pain, nausea, vomiting and diarrhea (at treatment of echinococcosis) - a reversible alopecia (poredeniye and moderate loss of hair) - fever Sometimes - reactions of hypersensitivity, including rash, an itching and urticaria - a leukopenia - hepatitis Very seldom - the pancytopenia, aplastic anemia, an agranulocytosis Patients with liver pathology, including hepatic echinococcosis, are more predisposed to suppression of a funtskiya of marrow. - the multiformny erythema, Stephens-Johnson's syndrome of the Contraindication - hypersensitivity to an albendazol and other components of medicine - eye retina pathology - the existing or planned pregnancy, the lactation period - children's and teenage age do18 Medicinal interactions Cimetidinum, a praziquantel and dexamethasone increase years plasma levels of a metabolite of an albendazol responsible for system efficiency of a product. Ritonavir, Phenytoinum, carbamazepine and phenobarbital can potentially reduce plasma concentration of an active metabolite of an albendazol – an albendazol of sulphoxide. The clinical value of this fact is unknown, however can affect efficiency of drug, especially at treatment of system helminthoses. Patients have to be under observation of the doctor regarding efficiency of treatment that can demand purpose of the alternative mode of dosing or revision of the carried-out therapy. Special instructions in the course of treatment of patients the drug Intazol can existence at them the existing neurotsistitsirkoz will come to light, especially patients in a zone with high degree have a spread of tenozny infections. At the patients who are treated for a neurotsistitsirkoz and system gelmintny infections the neurologic symptoms against the background of administration of drug connected with death of parasites can be shown. Attacks, increase in intracranial pressure and focal symptoms belong to these symptoms. Symptoms can be shown right after the beginning of therapy and demand immediate treatment by steroids and antikolvulsant. Oral or intravenous corticosteroids are recommended for use at the beginning of the first week of therapy for prevention of episodes of intracranial hypertensia. Perhaps weak or moderate increase in level of hepatic enzymes which it is normalized after the termination of administration of drug. In the course of therapy, cases of development of hepatitis were revealed. Definition of indicators of function of a liver has to be carried out before each cycle of treatment and each two weeks during treatment. If indicators of transaminases increase twice and more, drug needs to be cancelled. Treatment is resumed when indicators of function of a liver return to norm, but patients have to be under observation of the attending physician. Reception of an albendazol can cause suppression of function of marrow in this connection blood tests have to be made at the beginning and each two weeks during each 28-day cycle. Patients with liver diseases, including hepatic echinococcosis, have more expressed tendency to suppression of marrow conducting to a pancytopenia, aplastic anemia, an agranulocytosis and a leukopenia that demands careful monitoring of a picture of blood. At clinically significant decrease in level of uniform elements of blood, administration of drug should be cancelled. Drug should be used with care in diseases of kidneys. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms the Side effects affecting ability of driving of vehicles and service of the mechanical equipment in the movement were not observed. Overdose Symptoms are not described. A form of release and packing On 1 tablet in blister strip packaging from aluminum foil and a film polyvinylchloride. On 1 planimetric packing together with the instruction for medical use in the state and Russian languages place in a cardboard pack. To Store storage conditions at a temperature not above 30 °C. To store out of children's reach! A period of storage 3 years not to use after an expiration date Prescription status According to the prescription Interpharma Producer, India 902, Vikram Tower, 16, Rajendra Palace, New Delhi - 110008 Owner of the registration certificate of Interpharma, India the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) of KazEvroFarm LLP Almaty, Kurmangaza St. 48 "and", office 9
the Develop Index 050000